The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: Results of a comparative study

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 2, 1999, Pages 173-177

  Pronk, L C ^a,b   Van Putten, W L J ^a   Van Beurden, V ^a   De Boer Dennert, M ^a   Stoter, G ^a   Verweij, J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Docetaxel; Fluid retention; Hydroxyethylrutosiden

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; MONOXERUTIN; VASOACTIVE AGENT;

ADULT; AGED; ARTICLE; ASCITES; BREAST CANCER; CONTROLLED STUDY; DOSE RESPONSE; EDEMA; FLUID RETENTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; TREATMENT FAILURE; WEIGHT GAIN;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASCITES; BREAST NEOPLASMS; EDEMA; HUMANS; HYDROXYETHYLRUTOSIDE; MIDDLE AGED; PACLITAXEL; PERICARDIAL EFFUSION; PLEURAL EFFUSION; TAXOIDS; WATER-ELECTROLYTE IMBALANCE;

EID: 0032925846     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050880     Document Type: Article

References (16)

1. Casley-Smith JR, Morgan RG, Piller NB (1993) Treatment of lymphedema of the arms and legs with 5,6-benzo-(α)-pyrone. N Engl J Med 329: 1158-1163
2. Cerny T, Kaplan S, Pavlidis N, Schöffski P, Epelbaum R, Van Meerbeek J, Wanders J, Franklin HR, Kaye SB, for the ECTG (1994) Docetaxel (taxotere) is active in non-small cell lung cancer: a phase II trial of the EORTC Clinical Trials Group. Br J Cancer 70: 384-387
3. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314-322
4. Deprez-Curely JP, Cluzan R, Pecking A (1985) Benzopyrones and postmastectomy lymphedemas. Double-blind trial of placebo versus sustained release coumarin with trioxyethylrutin (TER) In: Casley-Smith JR, Piller NB (eds) Progress in lymphology X. Proceedings of the Xth International Congress of Lymphology, Adelaide 1985. University of Adelaide, Adelaide Australia, pp 203-205
5. Fumoleau P, Chevallier B, Dieras V, Kerbrat P, Roche H, Krakowski I, Armand JP, Van Glabbeke M, Azli N, Riva A (1994) Evaluation of two doses of Taxotere (docetaxel) as first line in advanced breast cancer EORTC Clinical Screening Group report. Ann Oncol 5 [suppl 8]: 27
6. Krakowski I, Rios M, Fumoleau P, Chevallier B, Roche A, Kerbrat P, Dieras V, Azli N, Bougon N, Riva A, Lentz MA, Van Glabbeke M (1995) Phase II first line chemotherapy study with docetaxel (Taxotere) and prophylactic medication of retention in patients with metastatic or locally advanced breast cancer. European Clinical Screening Group. Proc Am Soc Clin Oncol 14: 97
7. Pazdur R, Lassere Y, Soh LT, Ajani JA, Bready B, Soo E, Sugarman S, Patt Y, Abbruzzese JL, Levin B (1994) Phase II trial of docetaxel (taxotere) in metastatic colorectal carcinoma. Ann Oncol 5: 468-470
8. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selesiags J, Van Vreckem A, Van Glabbeke M (1997) Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 15: 3149-3155
9. Piller NB, Morgan RG, Casley-Smith JR (1988) A doublen-blind, cross-over trial of O-(β-hydroxyethyl)-rutosides (benzopyrones) in the treatment of lymphedema of the arms and legs. Br J Plast Surg 41: 20-27
10. Riva A, Fumoleau P, Roche H, Dieras V, Tubiana-Hulin M, Klink-Alakl M, Oulid-Aissa D, Van Glabbeke M, Lebecq A, Van Oosterom AT (1997) Efficacy and safety of different corticosteroid premedications in breast cancer patients treated with Taxotere. Proc Am Soc Clin Oncol 16: 188A
11. Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, Van Oosterom AT, Kaye SB (1993) Coping with toxicities of docetaxel (Taxotere). Ann Oncol 4: 610-611
12. Sternberg CN, Ten Bokkel Huinink WW, Smyth JF, Bruntch V, Dirix LY, Pavlidis NA, Franklin H, Wanders S, Le Bail N, Kaye SB (1994) Docetaxel (Taxotere) a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group study. Br J Cancer 70: 376-379
13. Sulkes A, Smyth J, Sessa C, Van Oosterom AT, Vermorken J, Kaye SB, Le Bail N, Verweij J, for the EORTC Early Clinical Studies Group (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 70: 380-383
14. Verweij J (1995) Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas. Anticancer Drugs 6 [Suppl 4]: 19-24
15. Wadworth AN, Faulds D (1992) Hydroxyethylrutosides. A review of their pharmacology and therapeutic efficacy in venous insufficiency and related disorders. Drugs 44: 1013-1032
16. Wanders J, Van Oosterom AT, Gore M, Piccart M, Wolff I, Kaplan S, Roelvink M, Franklin H, Kaye SB, for the EORTC Clinical Trials Group (ECTG), and Bayssas M, for Rhone-Poulenc Rorer (1993) Taxotere toxicity - protective effects of premedication. Eur J Cancer 29A [Suppl 6]: S206